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Abstract. The search for the basic defect in cystic fibrosis 
(CF) has reached a decisive stage since the recent iden- 
tification of the responsible gene. Electrophysiological 
and biochemical research ad defined the CF defect as a 
dysregulation of epithelial chloride channels. The puta- 
tive protein product of the now identified gene shares 
properties with other known transport proteins, but it is 
not necessarily itself a chloride channel protein. Elucida- 
tion of the primary cellular defect will certainly have im- 
portant aetiological and hopefully therapeutic implica- 
tions. The identification of the major gene mutation al- 
ready has significant consequences for genetic counsel- 
ling and prenatal diagnosis. Heterozygote detection at 
the population level awaits identification of the probably 
heterogenous mutations on about 30% of the CF chro- 
mosomes. At present, about 50% of CF patients are 
homozygous for the recently identified major CF muta- 
tion. 
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Introduction 
Cystic fibrosis (CF) is the most frequent autosomal re- 
cessive disease among Caucasians with an incidence of 
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approximately 1:2500. Clinical manifestations include 
serious malfunctioning of the respiratory tract, as well as 
the pancreas and intestines. The elevated NaC1 content 
of sweat in CF patients is used in diagnosis. Progress in 
the clinical management of the disease is the topic of the 
accompanying paper by Neijens et al. [47]. 
A disturbed function of exocrine gland epithelia is 
the common feature of the affected organs in CF pa- 
tients. Unravelling epithelial anion transport mechanisms 
and their regulation is thought to be a major step to- 
wards the elucidation of the primary protein defect in 
CF. The alternative approach in the search for the basic 
defect is molecular genetics. After the identification of 
closely linked DNA markers this has recently (1989) re- 
sulted in the identification of the CF gene and its most 
common mutation [39, 52, 54]. We will review the pre- 
sent state of knowledge on epithelial anion transport sys- 
tems in relation to the postulated properties of the CF 
gene product. 
The availability of closely linked polymorphic DNA 
markers already had considerable impact in genetic oun- 
selling and prenatal diagnosis. The clinical genetic impli- 
cations of the detection of the major CF mutation will be 
discussed. 
CF: the gene and its genetic markers 
The search for the gene 
When the primary protein defect in a genetic disease is 
still unknown, the first requirement for tracing the re- 
sponsible gene is chromosomal localisation. The demon- 
stration of linkage of the CF mutation to protein and 
DNA markers in 1985 led to the assignment of the CF 
locus to chromosome 7@1 [21, 42, 58, 60, 61]. The Met 
oncogene locus and the anonymous DNA marker J3.11, 
which are about 1500 kilobases apart, were identified as 
the probable borders of the CF gene-containing region 
[2, 20, 49]. 
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Molecular genetic research employed strategies to 
isolate fragments from "hypomethylated CpG islands" 
(sequences that are often associated with genes) and sat- 
uration mapping to find closer marker sequences at7q31, 
which narrowed the "CF region" to an area of approxi- 
mately 350-500 kilobases [23, 25, 36, 53]. The applica- 
tion of chromosome walking and jumping techniques led 
to the identification of a gene sequence that is expressed 
in the epithelia involved in CF [52, 54]. The predicted 
protein structure of the gene product shows properties of 
a membrane protein with a transport function, possibly 
but not necessarily a chloride channel [52]. In the ab- 
sence of a confirmatory test at the protein level, evi- 
dence that this cystic fibrosis transmembrane conduc- 
tance regulator (CFTR) gene is in fact the CF gene rests 
on genetic arguments. 
The search for the gene had previously produced a
set of very closely linked polymorphic DNA markers, 
some of which are in strong linkage disequilibrium with 
CF [22, 25, 53]. The preferential cosegregation f a de- 
fective CF gene with a specific haplotype of polymorphic 
alleles has led to the estimate that over 85% of CF chro- 
mosomes of North West European origin may carry the 
same mutation [22]. Indications for the occurrence of 
more than one mutation were derived from linkage dis- 
equilibrium comparisons between different ethnic groups 
[12, 24, 45] and between patients with well defined clini- 
cal differences, such as pancreatic involvement versus 
pancreatic sufficiency [18, 38]. 
Kerem et al. [39] identified a three base pair deletion 
in a CF counterpart of the normal CFTR gene. This de- 
letion was subsequently found on 70% of CF chromo- 
somes, in other words about half of the CF patients are 
homozygous for the three base pair deletion. The dele- 
tion was almost exclusively associated with the haplo- 
type that shows the highest linkage disequilibrium with 
CF and it was never found on normal chromosomes. 
These data provide strong evidence that the CFTR gene 
is the gene that is involved in CF and that the three base 
pair deletion is its most common mutation. This major 
mutation is found more often among patients that suffer 
from pancreatic insufficiency than among the pancreatic 
sufficient group [39]. The number of mutations that re- 
main to be identified is estimated to be greater than 
seven [39]. 
Clinical genetic applications 
The available polymorphic markers have also played a 
significant role in genetic ounselling and prenatal diag- 
nosis. For nearly all couples with a 1:4 recurrence risk 
seeking prenatal monitoring of the next pregnancy a
fully informative pattern of polymorphic alleles may be 
established, provided that DNA from an index patient is 
available. The ensuing reliability of prenatal prediction 
is over 99% in the majority of cases, as some of the most 
informative markers map at a genetic distance of only 
+ 0.1cM (0.1% chance of recombination) from the CF 
mutation [27]. An important aspect is that DNA analysis 
allows 1st trimester diagnosis after chorionic villus sam- 
pling, while the alternative test, the assay of fetal micro- 
villar enzymes measuring a secondary phenomenon of 
the disease in amniotic fluid, does not reach maximum 
reliability until the 17th-18th week of pregnancy [9, 11, 
46]. The result of a prenatal DNA test is usually avail- 
able about 1 week after chorionic villus sampling, when 
conventional methods of restriction enzyme digestion, 
Southern blotting and hybridisation with radioactively 
labelled DNA probes are applied. When informativity is
found for those polymorphisms that are suitable for di- 
rect detection after DNA amplification a same-day diag- 
nosis is possible [28, 48, 62]. 
The obvious limitation of linkage analysis is that its 
application is restricted to prenatal diagnosis and carrier 
identification within families, where a DNA sample of 
an index patient is available. In other words, linkage 
analysis is dependent on marker haplotype information 
from the propositus' DNA and the results are valid only 
within the same family. 
The identification of the major CF mutation, for which 
about 50% of the patients are homozygous, implies that 
mutation analysis may now replace linkage analysis in 
about 50% of the pregnancies at a 1:4 risk of CF [32]. 
The requirement is that both parents how heterozygos- 
ity for the deletion. In these cases, early prenatal diag- 
nosis of CF becomes index patient-independent a d will 
also be accessible to parents whose only affected child 
has deceased in the absence of material to study linkage 
phase. The deletion can be analysed by amplification of 
the relevant region of the gene and detection of the nor- 
mal and deleted alleles with specific oligonucleotides 
[32, 391 .
The possibilities for carrier detection are still differ- 
ent for individuals with and without a family history of 
CF. In principle, the carrier status of close relatives of 
CF patients can be established with the same restrictions 
that apply to prenatal diagnosis. Mutation analysis may 
substitute for linkage studies when the individual has an 
affected sib who is homozygous for the deletion or an 
unaffected (carrier) sib who is heterozygous for the dele- 
tion. 
When there is no family history of CF, members of a 
Caucasian population have an average risk of 1:25 of 
being a CF carrier. Haplotyping for those markers that 
are in linkage disequilibrium with CF has been applied 
for risk modification. Haplotypes may be discriminated 
that are at high or at low risk of being associated with CF. 
The predictive value of haplotype analysis with markers 
like XV2c, KM19 and CS-7 may significantly alter the 
population risk, to an upper limit of about 1:5 and a 
lower limit of about 1 : 300 [3, 26]. The first option now 
would be to test for the presence of the three base pair 
deletion. About 70% of carriers would be identified in 
this way, equivalent o 1:35 members of a Caucasian 
population. When an individual is shown to be free of 
the deletion, studying markers at linkage disequilibrium 
with CF may be of limited value, because the observed 
disequilibrium largely coincides with the presence of the 
three base pair deletion and because the remaining de- 
fects are obviously much more heterogeneous. 
The now available knowledge of the CF gene sequence 









~ _~ 3Na + 
J ~ K + 
LUMEN 
I i 










Fig. 1. Model of cells that reabsorb NaC1 
(a) or secrete NaC1 (b). The cells share an 
ATP dependent 3Na/2K-pump rotein, 
which constitutes the primary driving 
force for sodium and chloride movement, 
and a chloride channel protein. In (a) 
sodium is driven into the celt, down its 
electrochemical gradient through an 
apical sodium channel protein, followed 
by chloride. In (b) a basolateral Na-K-2C1 
symport protein, energised by the sodium 
and potassium gradient that is set up by 
the 3 Na/2 K pump, concentrates chloride 
ions above lectrochemical equilibrium in 
the cytosol of the cell. When in this cell 
the apical chloride channel is activated, 
chloride ions will flow out of the cell 
followed by sodium ions through the 
paracellular junction pathway [31] 
that cause CF. Identification of all CF mutations would 
allow prenatal diagnosis without restrictions as well as 
screening for CF carriers without remaining uncertain- 
ties. 
The next sections review the present knowledge on 
the presumed cellular site that is affected by the CF mu- 
tations, and the possible roles of the normal and deleted 
CFTR gene products. 
pA 
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Disturbed chloride transport in cystic fibrosis epithelia 
CF is characterised by meconium in the gastro-intestinal 
tract, obstruction of the airways and malfunction of the 
pancreas. The dehydrated obstructions in these CF or- 
gans could result from a decreased secretion or increased 
reabsorption of fluid and electrolytes. This hypothesis 
will be discussed in this section. 
Secretion or reabsorption of water in the organs in- 
volved in CF results from the transport of salt, mainly 
sodium and chloride ions, across the epithelial cells (Fig. 1) 
that line the outer border of these organs. When ducts of 
normal and CF sweat glands are studied with electro- 
physiological methods it appears that the transepithelial 
potential difference is elevated in the CF duct [6, 50, 51]. 
This observation, combined with the finding that the 
NaCI concentration i the sweat of CF patients is ele- 
vated, provides firm evidence for a decreased chloride 
permeability of the CF sweat duct [5], apparently due to 
a latency of chloride channel activation (Fig. 1). Alterna- 
tively, the increased potential difference in CF nasal epi- 
thelium [40] could result from a combined increase in 
reabsorption of sodium ions e.g. CF nasal polyp cells 
have an increased number of sodium channel proteins or 
3 Na-2 K-ATPase transport proteins and decreased reab- 
sorption of chloride ions [41]. At present, the most de- 
tailed studies have been focussed on the defect in chloride 
channel activation. 
An elegant echnique to study chloride channel regu- 
lation in intact cells and in isolated membrane patches is 
patch-clamp analysis of single ion channels [33]. A patch 
-80 _~--'~ I ~ +80 (mV) 
Fig. 2. Current o voltage relationship of the chloride channel with 
different anion composition of the bath (b) and pipette (p) Ringer 
solution. ~ ,  150mM C1 b/150mM C1 p; 9 O, 15mM 
Cl-b/150 mM Cl-p; [] El, 400 mM Ct-b/150 mM Cl-p 
of membrane is sealed onto the tip of a micropipette 
while the current through the innate channels is mea- 
sured by applying a clamp potential across the mem- 
brane. The channel activity and its regulation can be 
studied in on-cell patches and excised, cell-free, patches. 
Furthermore, a given channel can be characterised utilis- 
ing different ion gradients (Fig. 2) across the membrane. 
Patch clamp analysis has shown that several chloride 
channels with distinct characteristics are present in epi- 
thelial cells [57]. 
The channel of interest in CF cells appears to be a 
30-50 pS conductance chloride channel that is voltage 
rectifying. A characteristic observed only in the excised 
patch condition is the voltage activation phenomenon. 
Apparently, the chloride channel remains ilent in a cell- 
673 
free patch when the clamp potential is held at physiolog- 
ical value. However, the application of depolarising volt- 
ages leads to rapid channel activation in normal tissue, 
even in the absence of physiological activating signals. 
Most importantly, depolarising conditions unmasked 
"latent" chloride channels in CF tissue. These channels 
display characteristics similar to the voltage activated 
channels of normal tissue [10, 43, 56], which argues 
strongly against a mutation in the conductive part of the 
channel or a channel recruitment defect in CF. Instead, 
the CF defect is most plausibly located in a regulatory 
component as part of the channel gating mechanism 
operating under physiological conditions in the intact 
cell, as will be delineated in the section regulation. 
Regulation of chloride channels: 
a search for the molecular basis of chloride channel 
dysregulation in cystic fibrosis 
Up- and down-regulation of C1- channel activity by 
neurotransmitters and hormones is triggered in most 
cells through hormone-induced changes at the level of 
intracellular second messengers, uch as cyclic nucleo- 
tides, calcium (Ca2+), and diacylglycerol (DAG) [32, 
33]. Hypothetically, cyclic nucleotide and Ca -+ regula- 
tion of ion channels may occur through: 
(1) a direct interaction with an allosteric modifier site on 
the channel protein itself; 
(2) channel recruitment through fusion of channel-con- 
taining intracellular membrane vesicles with the plasma 
membrane; and 
(3) phosphorylation f a regulatory (sub)unit of the C1- 
channel by cyclic adenosine monophosphate (cAMP)-, 
2+ cyclic guanosine monophosphate (cGMP)- or Ca /DAG- 
dependent protein kinases. 
Cyclic nucleotide-dependent pro ein kinases 
Direct evidence in favour of the phosphorylation model 
has been obtained recently in patch clamp studies of ex- 
cised membrane patches from human tracheal ceils [43, 
56], lymphocytes [10] and colon carcinoma cells [17]. Ex- 
posure of the inside-out patch to the catalytic subunit of 
cAMP-dependent protein kinase (PK-A) and adenosine 
triphosphate (ATP) under conditions preventing voltage 
activation resulted in phosphorylation-induced activa- 
tion of the C1- channel that could be reversed by an en- 
dogenous protein phosphatase. In contrast, the addition 
of cyclic nucleotides and/or calcium alone was unable to 
promote C1- channel activation [17, 56]. 
Most importantly, the addition of PK-A plus ATP to 
a CF patch failed to activate its C1- channel, which could 
subsequently be unmasked by voltage activation [10, 43, 
56]. These experiments have narrowed own the search 
for the CF defect o a step in the cAMP activation of the 
C1- channel distal to PK-A but upstream of the conduc- 
tive (sub)unit of the channel. 
The search for a membrane phosphoprotein serving 
as a key regulator of the C1- channel has been stimulated 
by the discovery of a unique enzyme with cGMP-depen- 
dent protein kinase activity (PK-G). This enzyme has so 
far been found exclusively in the intestinal brush border 
and is capable of activating the intestinal Ct- channel in 
response to cGMP itself or to a specific activator of the 
cGMP-generating enzyme guanylate cyclase, i.e. heat- 
stable Escherichia coli enterotoxin [13, 14]. Measure- 
ments of CI- secretion in intestine from CF patients with 
meconium ileus have demonstrated a defect in cGMP 
activation of the CI- channel at a site distal to PK-G 
[1, 4, 15]. 
Ca 2 + /DA G signals 
Less information is available about he molecular mech- 
anisms by which Ca 2+ and DAG modulate the activity of 
epithelial CI- channels. Both signals are generated by a 
variety of stimuli, such as acetylcholine, bradykinin and 
histamine. The first step is the activation of phospholi- 
pase C, which catalyses the release of both inositoltris- 
phosphate, a Ca2+-mobilising signal, and DAG from in- 
ositolphospholipids in the plasma membrane. Ca 2+ sig- 
nals may activate the CI- channel either through cou- 
pling to a high-affinity Ca 2-- binding protein (e.g. the CF 
antigen [19]?), which serves as a dissociable subunit of 
the channel or through a Ca2+-dependent protein kinase 
catalysing channel phosphorylation. DAG acts as a pro- 
tein kinase C (PK-C) activator. Experiments with en- 
terocytes and with airway epithelial membrane patches 
have shown that PK-C may play a double role, as epithe- 
lial CI- channels may both be up- and down-regulated 
[17, 44]. Activators of PK-C like phorbolesters are cap- 
able of activating the channel in the absence of other 
stimuli, but promote a rapid closure of the channel fol- 
lowing its preactivation by Ca a+ or cyclic nucleotides 
[17]. These results can be explained by postulating a sec- 
ond phosphorylation site on the channel or on a channel 
regulator that acts as an inhibitory modifier (P2 in Fig. 3) 
and is recognised by PK-C solely if the stimulatory site is 
prephosphorylated by PK-A, PK-G, or PK-C. 
The effect of Ca 2§ and PK-C on CI- channels in CF 
tissues is not uniform. The Ca 2+ activation of the chan- 
nel is defective in CF sweat gland duct and intestine, but 
remains unaffected in CF trachea and sweat gland coil, 
whereas PK-C fails to activate CI- channels in most CF 
tissues, such as trachea, sweat gland duct and intestine 
[15, 16, 35, 44, 63]. The molecular basis for the different 
sensitivities of the CI- channel to Ca2+/DAG signalling 
(i.e. cholinergic stimulation) in various CF epithelia is 
not yet elucidated. Interestingly, voltage activation of 
CI- channels in excised patches from CF tracheal cells 
could still be reversed by PK-C in the presence of Ca 2+, 
indicating that the inhibitory phosphorylation site (P2) 
functions normally in CF [44]. 
The data summarised here allow the following con- 
clusions: 
1. Both the secretory CI- channel in CF intestine and 
the absorptive C1- channel in CF sweat duct are insensi- 
tive to all (patho)physiological activators known so far 
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Fig. 3. Hypothetical models indicating possible relationships be- 
tween the CF gene product CFTR and epithelial chloride channels. 
a CFTR (predicted structure modified from [52]) is depicted as a 
CI- conducting transmembrane protein containing additional sites 
for ATP binding (dotted area) and phosphorylation (regulatory 
domain R). Phosphorylation of CFTR at P1 activates the chan- 
nel, whereas phosphorylation at P2 inactivates the channel. When 
phenylalanine is deleted from an ATP binding domain, its neces- 
sary interaction with the regulatory domain is affected, b CFTR is 
depicted as a pump protein, which influences the activity of the 
C1- channel (Cl CH) by adjusting the level of a specific CI- chan- 
nel inhibitor (INHIB). The deletion of phenylalanine from an ATP 
binding domain of CFTR impairs ATP-driven extrusion of the 
channel inhibitor, thereby resulting in a (reversible) blockade of 
the channel. The CI- conducting domain remains unaffected, in 
agreement with the observed voltage activation of the channel in 
excised membrane patches. The asterisk shows the major mutation 
site in cystic fibrosis 
sation. The apparent protective ffect of the CF muta- 
tion against secretory diarrhoea, e.g. cholera, could pos- 
sibly explain the high incidence of CF in the Caucasian 
population [7]. 
2. The insensitivity of the C1- channel in CF towards 
multiple independent signals (cAMP, cGMP, DAG; Ca 2§ 
in some tissues) is indicative for either: (1) a defect in a 
common regulatory step distal to PK-A, PK-G and PK-C, 
e.g. a functionally important domain or subunit of the 
C1- channel (Fig. 3A); (2) the accumulation of an (as yet 
unidentified) intracellular inhibitor of C1- channel phos- 
phorylation and function (Fig. 3B), or (3) hyperactiva- 
tion of an enzyme involved in down-regulation of the 
channel, e.g. PK-C or a protein phosphatase. The latter 
model would explain some additional abnormalities in 
other cellular functions controlled by the same regula- 
tory enzymes, such as the upregulation of Na § channels 
in CF trachea [8] and the induction of apical K § channels 
in CF intestine [15, 16]. However, this model has be- 
come less plausible since the recent identification of the 
CF gene, suggesting that the CF gene product bears no 
resemblance to PK-C or protein phosphatases and is also 
unlikely to function as a regulatory protein of kinases or 
phosphatases. 
Identification of the CF gene: 
does it encode a chloride channel protein? 
The putative CF gene product CFTR shows considerable 
homology with a family of ATP-dependent transport 
proteins that includes the mammalian multidrug resis- 
tance P-glycoprotein (MDR) [52]. The now identified 
major CF mutation accounts for about 70% of the de- 
fects. This three base pair deletion results in an in-frame 
deletion of a phenylalanine r sidue from one of the puta- 
tive ATP-binding domains in CFTR [52], which appar- 
ently causes chloride channel dysfunction. However, a 
crucial role of an ATP binding site is a typical feature of 
pump proteins rather than of ion channels. On the other 
hand, charged amino acids occur in the membrane-span- 
ning part of the protein and a unique cytoplasmic do- 
main carries multiple potential phosphorylation sites for 
PK-A and PK-C [52] (Fig. 3). On the basis of the latter 
characteristics CFTR may still be a chloride channel pro- 
tein. 
In this respect it is interesting to note that ATP has 
always been included in excised patch experiments with 
PK-A and PK-C. It was thought o be required solely as 
a co-substrate for these protein kinases, but now it seems 
that ATP may also be a ligand for the chloride channel 
itself (Fig. 3) [10, 35, 43, 44, 56, 57]. 
If CFTR were the chloride channel, it is relevant o 
mention that the epithelial channel-mediated transport 
of chloride ions follows their electrochemical gradient. 
Thus, transport per se does not require energy. There- 
fore, the ATP binding sites in CFTR may very well serve 
additional functions uch as the allosteric modification of 
channel conformation or the (auto)phosphorylation of 
the inhibitory phosphorylation site (P2 in Fig. 3) that 
keeps the channel in a closed state in the absence of 
stimulatory signals. 
Alternatively, the observed sequence similarity be- 
tween the MDR and the CFTR genes may be accom- 
panied by a direct functional similarity between their 
products. When cancer cells become resistant to a num- 
ber of unrelated rugs simultaneously, this is due to the 
MDR gene-encoded P-glycoprotein, which acts as a pump 
protein that removes toxins from the cells [37]. CFTR 
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might act as a pump to adjust he intracellular level of 
chloride channel-inhibitors by mediating their transport 
across the epithelial membrane (Fig. 3b). 
These considerations regarding the function of CFTR 
are based on its presumed localisation in the plasma 
membrane. Until alternative cellular localisations have 
been excluded, such as the endoplasmic reticulum or 
Golgi membranes, it may even be conceivable that CFTR 
plays a role in the post-translational modification or 
membrane insertion of the chloride channel protein. 
At present, any prediction about he function of CFTR 
is based entirely on DNA sequence homologies with 
genes that encode proteins with known transport func- 
tions. Speculations still have to be substantiated by gene 
expression studies, protein purification and reconstitu- 
tion experiments. At this stage it would not be justified 
to localise the CF defect in epithelial chloride channels. 
In any case, the study of CFTR structure and function is 
likely to provide important new insights into the molecu- 
lar properties and regulation of epithelial anion channels 
in general. Since the CF defect apparently conveys pro- 
tection from secretory diarrhoea it would be conceivable 
that specific chloride channel inhibitors may find future 
application as antidiarrhoeal gents. On the other hand, 
these studies may trigger the development of a chloride 
channel agonist capable of correcting or bypassing the 
defect in CF. 
Concluding remarks 
The identification of the CFTR gene is expected to have 
significant clinical consequences hopefully including new 
therapeutic perspectives. 
At the diagnostic level the analysis of the three base 
pair deletion will replace linkage analysis to a certain ex- 
tent. Deletion analysis introduces the possibility of early 
prenatal diagnosis for 50% of the couples who lost their 
only affected child, i.e. when both parents are hetero- 
zygous for the same deletion. In the remaining cases 1st 
trimester diagnosis using closely linked markers will still 
rely on marker information from index patient and par- 
ents. 
The three base pair deletion detects about 70% of CF 
carriers. Already the debate has started whether or not 
this is sufficient to start screening for CF carriers in the 
population [30, 52]. As discussed above, testing persons 
without a family history of CF by deletion analysis would 
identify about 1 : 35 of them as carriers. For the others 
the remaining risk of being a carrier would be difficult o 
establish. The use of a statistical pproach based on link- 
age disequilibrium will be hampered by the expected 
heterogeneity n the other mutations that cause CF. An 
unequivocal carrier test awaits the identification of the 
other gene defects. To this end the investigators who 
identified the gene and the Cystic Fibrosis Foundation 
(USA) have initiated aconsortium of laboratories, which 
have been involved in CF research and/or diagnostics 
(L-C Tsui, personal communication). The aim is to dis- 
tribute experimental materials and protocols and to col- 
lect results and population data, which would regulate 
the search for the other mutations in the most efficient 
way. 
The identification of the CFTR gene is also a major 
step towards unravelling the pathophysiology of CF. 
Subsequent s udies hould reveal the role of the normal 
CFTR gene product in chloride channel function. The 
next important question is how the deletion of a single 
amino acid in a nucleotide binding domain affects chloride 
transport. As was outlined above a functional impair- 
ment of the protein may be envisaged, even though the 
missing phenylalanine does not belong to the supposedly 
crucial amino acids for ATP binding [34]. Alternatively, 
the deletion of a phenylalanine may prevent CFTR to 
reach its site of action, analogous to the functionally un- 
affected products of the alpha-l-antitrypsin deficiency 
alleles Z and Mmalton. The Z variant contains a single 
amino acid substitution and Mmalton has an inframe de- 
letion of phenylalanine. Apparently, both mutations 
prevent normal processing and result in impaired secre- 
tion and intracellular accumulation of alpha-l-antitryp- 
sin [29]. Possibly, the deletion of phenylalanine from 
CFTR would represent a membrane-insertion defect. 
The feasibility of curative protein therapy in CF pa- 
tients will be strongly dependent on the nature and the 
cellular site of the defect. The identification ofthe CFTR 
gene will enable molecular biologists, electrophysiologists 
and biochemists o combine their efforts in finding the 
basic CF defect. The search for other mutations i likely 
to reveal additional crucial regions of the gene. It is to be 
expected that some of the answers will be generated by 
correction studies, experimental designs aimed at resto- 
ration of the mutant phenotype in CF epithelial ceils 
through expression of the normal gene sequence or the 
administration of the normal gene product. Recently, 
immortalised nasal polyp epithelial cell lines from a CF 
patient were described, which had retained the mutant 
phenotype in patch clamp studies [55] and which were 
shown to be homozygous for the phenylalanine d letion 
(unpublished observation). These cell lines seem suit- 
able targets for correction studies and may eventually 
even serve as in vitro model systems for (gene) therapy 
in CF. 
The concept of gene therapy of genetic diseases is 
still theoretical. However, the progress towards gene 
therapy of diseases that might be cured through correc- 
tion of haemopoietic stem cells using modified retroviral 
vectors has been impressive [59]. Experiments carried 
out in vitro and later on in animal models hould provide 
the conditions to reach and stably transfect the target is- 
sues in CF. 
At present, hese considerations are necessarily specu- 
lative. There is, however, no doubt that the search for 
the basic CF defect has been given a new direction after 
the identification of the responsible gene. 
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